PXPei Xu

Pei Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pei Xu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Bao-Yi Huang

    Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Reproductive Medicine Center of the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Dun-Jin Chen

    Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Reproductive Medicine Center of the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Han Lin

    Department of Gynecology of Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Jia-Hui Zhan

    Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Reproductive Medicine Center of the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Jianqiao Liu

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou

    1 shared publication
  • Kaichi Ma

    Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study

    by Miaoxian Ou, Pei Xu, Han Lin, Kaichi Ma, Mingxing Liu

    Objective. The relationship between metabolic risk and ovarian function is ambiguous. This retrospective study analyzed the medical records of 461 PCOS patients collected between January 2019 and June 2020 to investigate the relationship between serum anti-Müllerian hormone (AMH) and parameters of metabolic risk in the population with polycystic ovary syndrome (PCOS). Methods. A total of 461 PCOS patients aged 2040 years were included and stratified into four groups according to the AMH level. The association between AMH and the parameters related to metabolic risk in these groups was compared, and the discrepancies were further explored. Binary logistic regression was performed to examine the risk factors of HOMA-IR. The values of AMH that best predicted the risk of HOMA-IR were also analyzed by ROC curves. Results. AMH was negatively associated with HOMA-IR (odds ratio (OR) 0.279, 95 confidence interval (CI) 0.36 to 0.20), fasting insulin (OR 0.282, 95 CI 0.36 to 0.20), 1-hour postprandial insulin (OR 0.184, 95 CI 0.28 to 0.11), 2-hour postprandial insulin (0.180, 95CI 0.28 to 0.11), 3-hour postprandial insulin (OR 0.198, 95 CI 0.30 to 0.13), waist-hip ratio (OR 0.235, 95 CI 0.31 to 0.14), and body mass index (OR 0.350, 95 CI 0.43 to 0.27). There was no statistically significant relationship between blood pressure, serum glucose profile, or lipid levels and AMH. Binary logistic regression showed that AMH protected against the occurrence of PCOS patients (OR: 0.835, 0.776, and 0.898). For the prediction of HOMA-IR, AMH had an AUC-ROC of 0.704 (95 CI 0.6520.755) with a cutoff value of 7.81mmol/L, a sensitivity of 70.3, and a specificity of 70.1. Conclusions. Higher AMH levels were significantly associated with a lower insulin profile and might be a useful predictor for HOMA-IR in PCOS patients.


  • Insulin Reduces Reaction of Follicular Granulosa Cells to FSH Stimulation in Women With Obesity-Related Infertility During IVF

    by Pei Xu, Bao-Yi Huang, Jia-Hui Zhan, Man-Ting Liu, Yang Fu, You-Qiang Su, Qing-Yuan Sun, Wei-Hua Wang, Dun-Jin Chen, Jian-Qiao Liu

    Context Obese women usually need larger doses of FSH for ovarian stimulation, resulting in poor outcomes; however, the mechanism is still unclear. Objective To investigate the molecular regulation of FSH receptor (FSHR) expression associated with obesity. Design Case-control study to improve IVF outcomes. Patients Eighty-two obese and 457 overweight women undergoing IVF and 1,790 age-matched controls with normal weight from our reproductive medicine center. Intervention No special. Main Outcome Measures FSHR expression was decreased in parallel with BMI, while the oestradiol (E2) level on the hCG trigger day was significantly lower. Results FSHR expression in hGCs, both mRNA (P = 0.02) and protein (P = 0.001) levels, was decreased in overweight/obese women. Both insulin (P < 0.001) and glucose (P = 0.0017) levels were positively correlated with BMI in fasting blood and follicle fluids(FF) but not with FF leptin level. Treated KGN cells with insulin, E2 production was compromised, the level of p-Akt2 decreased while p-GSK3 increased, similar changes in hGCs from obese women. Stimulated hGCs from obese women with CP21, an inhibitor of GSK3β, resulting in upregulated β-catenin activation and increased FSHR expression. CP21 also increased the expression of IRS-1 and PI3K as well as the p-Akt2. Conclusions Obesity was associated with reduced FSHR expression and E2 production in IVF women, caused by dysfunctional insulin pathway. Decreased FSHR expression in hGCs from obese women and insulin-treated KGN could be rescued by inhibition of GSK3β, which might be a potential target for improving the impaired FSH response in obese women.


  • A Pooled Analysis of The Clinical Utilities of Long Non-Coding RNA Based Molecular Signature for Diffuse Large B Cell Lymphoma

    by Pei Xu, Xiaoli Chen, Panke Su

    Long non-coding RNAs (lncRNAs) have been highlighted as promising biomarkers for several types of malignancies. The current meta-analysis sought to investigate the clinical value of lncRNA-based molecular signatures as biomarkers for diagnosis, subtype classification, and prognosis in diffuse large B cell lymphoma (DLBCL). A systematic search of the online databases was carried out and data were retrieved by pairs of independent reviewers. Effect sizes of the diagnostic parameters were combined using a quantitative meta-analysis. In the prognostic analysis, hazard ratio (HR) with 95% confidence interval (CI) for the primary endpoints of overall survival (OS) and progression-free survival (PFS) were meta-analyzed. Our data exhibited that lncRNA expression profiling harvested a pooled sensitivity of 0.87 (95% CI: 0.78 - 0.92), specificity of 0.84 (95% CI: 0.75 - 0.90), and AUC of 0.92 in distinguishing DLBCL cases from cancer-free participants. For subtype classification, lncRNA signature could discriminate germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL cases with an estimated sensitivity of 0.92 (95% CI: 0.89 - 0.95), specificity of 0.89 (95% CI: 0.83 - 0.93) and AUC of 0.96. Prognostic analysis manifested that altered lncRNA profiles predicted unfavorable clinical outcomes of DLBCL in OS (univariate analysis: HR = 1.45, 95% CI: 1.14 - 1.83, p < 0.001). Further subgroup study stratified by clinicopathological features revealed that the LDH level, IPI score, subtype, and testing pattern of lncRNAs were markedly correlated with the OS in DLBCL. Collectively, our data uncover that lncRNA expression profiling retains a relatively high accuracy in the diagnosis and classification of DLBCL. Altered levels of lncRNAs are also closely associated with worse OS and appeared to be powerful predictors in forecasting prognosis in DLBCL.